Shares of AET now seen reaching $37, according to Goldman Sachs. Estimates also lowered, as the company faces multiple headwinds. Neutral rating.

ARG was downgraded from Buy to Hold, Keybanc said. APD will likely have to raise its bid, but the risk/reward is no longer as attractive.

BMRN was downgraded from Buy to Hold, Brean Murray said. Valuation call, as the stock is already pricing in good news from Phase 2 products.

LRN downgraded to Neutral from Outperform as state budget pressures could weigh on the company's margins and revenue. Price target remains at $20.

Shares of BSX now seen reaching $9, according to Goldman Sachs. Estimates were also lowered, because of deteriorating industry pricing. Neutral rating.

ETFC estimates were reduced through 2011, FBR Capital Markets said. Company is cutting is commissions, because of price competition. Outperform rating and new $2 price target.

Shares of FSLR now seen reaching $125, Deutsche Bank said. Estimates also lowered, to reflect difficult industry fundamentals. Hold rating.

STJ was added to the Conviction Sell list, Goldman Sachs said. $35 price target. Consensus estimates are likely to head lower, given the company's leverage to the ICD market.